Business
The following is a summary of the business for each reporting segment.
NISOURCE INC.: Revenue grew 23.5% to $6.523B from $5.283B. Net income grew 22.2% to $929.5M from $760.4M. Free cash flow remained negative, with the outflow narrowing from $832.5M to $420M. Operating margin expanded 59 bps to 28.14%. NISOURCE INC.'s annual comparison also shows the balance-sheet screen falls in the distress range and requires business-model context.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 23.5%OK
- Profitability — Net income grew 22.2% to $929.5M from $760.4MOK
- Cash flow — Free cash flow remained negative, with the outflow narrowing from $832.5M to $420MOK
- Margins — Operating margin expanded 59 bps to 28.14%OK
- Accounting — Distress-range screen needs contextWatch
- Insiders — 0 purchases and 8 salesNote
Where the revenue comes from
Fiscal 2025, as NISOURCE INC. reports it. History and quarterly detail are in the app.
- Columbia Operations$3.3B
- NIPSCO Operations$3.2B
Leadership changes
From NISOURCE INC.'s own filings, the day they're filed.
- John McAvoy · director · appointmenteff. 2024-03-19
Latest filings
- 8-K · Company announcement2026-08-18
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-08-05
- 8-K · Company announcement2026-05-18
- 8-K · Company announcement2026-05-12
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about NISOURCE INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.